XOMA Royalty Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

Condensed Consolidated Financial Statements Detail (Tables)

3 Months Ended

Mar. 31, 2017

Condensed Consolidated Financial Statements Detail [Abstract]

Property and equipment, net consisted of the following (in thousands):

	March 31,			December 31,
	2017			2016
Equipment and furniture	$	2,691		$	14,023
Leasehold improvements		554			554
		3,245			14,577
Less: Accumulated depreciation and amortization		(2,849	)		(13,541	)
Property and equipment, net	$	396		$	1,036

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

	March 31,		December 31,
	2017		2016
Accrued payroll and other benefits	$	123	$	1,582
Accrued clinical trial costs		394		743
Accrued incentive compensation		203		—
Accrued legal and accounting fees		670		385
Other		783		1,505
Total	$	2,173	$	4,215

Reconciliation of the Numerator (Net Loss) and the Denominator (Number of Shares) Used in the Calculation of Basic and Diluted Net Loss Per Share Available to Common Stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share available to common stockholders (in thousands):

	Three Months Ended March 31,
	2017			2016
Numerator
Net loss	$	(10,715	)	$	(8,365	)
Deemed dividend on convertible preferred stock		(5,603	)		—
Net loss available to common stockholders, basic and diluted	$	(16,318	)	$	(8,365	)

Denominator
Weighted average shares outstanding used for basic and diluted net loss per share available to common stockholders		6,887			5,978

Outstanding Securities Considered Anti-Dilutive

Potentially dilutive securities are excluded from the calculation of diluted net loss per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share available to common stockholders (in thousands):

	Three Months Ended March 31,
	2017		2016
Convertible preferred stock (as converted)		2,446		—
Common stock options and RSUs		653		535
Warrants for common stock		381		911
Total		3,480		1,446